Determinants of therapeutic lag in multiple sclerosis

I Roos; E Leray; F Frascoli; R Casey; JWL Brown; D Horakova; EK Havrdova; M Debouverie; M Trojano; F Patti; G Izquierdo; S Eichau; G Edan; A Prat; M Girard; P Duquette; M Onofrj; A Lugaresi; P Grammond; J Ciron; A Ruet; S Ozakbas; J De Seze; C Louapre; H Zephir; MJ Sá; P Sola; D Ferraro; P Labauge; G Defer; R Bergamaschi; C Lebrun-Frenay; C Boz; E Cartechini; T Moreau; D Laplaud; J Lechner-Scott; F Grand’Maison; O Gerlach; M Terzi; F Granella; R Alroughani; G Iuliano; V Van Pesch; B Van Wijmeersch; DLA Spitaleri; A Soysal; E Berger; J Prevost; E Aguera-Morales; P McCombe; T Castillo Triviño; P Clavelou; J Pelletier; R Turkoglu; B Stankoff; O Gout; E Thouvenot; O Heinzlef; Y Sidhom; R Gouider; T Csepany; B Bourre; A Al Khedr; O Casez; P Cabre; A Montcuquet; A Wahab; JP Camdessanche; A Maurousset; I Patry; K Hankiewicz; C Pottier; N Maubeuge; C Labeyrie; C Nifle; A Coles; CB Malpas; S Vukusic; H Butzkueven; T Kalincik

Journal article

Determinants of therapeutic lag in multiple sclerosis

I Roos, E Leray, F Frascoli, R Casey, JWL Brown, D Horakova, EK Havrdova, M Debouverie, M Trojano, F Patti, G Izquierdo, S Eichau, G Edan, A Prat, M Girard, P Duquette, M Onofrj, A Lugaresi, P Grammond, J Ciron Show all

Multiple Sclerosis Journal | Published : 2021

DOI: 10.1177/1352458520981300

Abstract

Background: A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups. Objectives: The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation. Methods: Data from MSBase, a multinational multiple sclerosis (MS) registry, and OFSEP, the French MS registry, were used. Patients diagnosed with MS, minimum 1 year of exposure to MS treatment and 3 years of pre-treatment follow-up, were included in the analysis. Studied outcomes were incidence of relapses and disability accumulation. Therapeutic lag was calculated using an..

View full abstract

University of Melbourne Researchers

Izanne Roos Author

Charles Malpas Author

Tomas Kalincik Author

Related Projects (3)

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

BIOMARKERS TO PREVENT DISABILITY IN MULTIPLE SCLEROSIS

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

Grants

Awarded by Merck

Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was supported by the EDMUS Foundation and NHMRC (1140766, 1129189 and 1157717). I.R. was supported by an MSIF-ARSEP McDonald fellowship grant and a Melbourne Research Scholarship. The MSBase Foundation is a not-for-profit organisation that receives support from Biogen, Novartis, Merck, Roche, Teva and Sanofi-Genzyme. The study was conducted separately and apart from the guidance of the sponsors. The Observatoire Francais de la Sclerose en Plaques (OFSEP) was supported by a grant provided by the French State and handled by the `Agence Nationale de la Recherche', within the framework of the `Investments for the Future' programme, under the reference ANR-10-COHO-002, by the Eugene Devic EDMUS Foundation against multiple sclerosis and by the ARSEP Foundation.